About the 50-State Network
Named after CreakyJoints co-founder and patient advocate Seth Ginsberg, the 50-State Network is a grassroots advocacy organization comprised of patients like you.
The 50-State Network is working to share the patient perspective, which is crucial in the State and Federal health policy and regulatory arenas. Patients need a voice in all conversations that relate to our access to treatment, safety, or the quality of our care.
Join and you’ll receive updates on impending legislation at both the national and state levels which could impact your healthcare and the healthcare for millions.
Joining the 50-State Network
Membership is free, and your participation is voluntary. After you fill out the fields below, you will receive a welcome packet and a member of our team will contact you to review your membership, and share more about steps you can take right away to become involved.
If there’s a pressing legislative issue where we need our voices heard, we’ll put the word out to the 50-State Network. We can then connect you with other network members in your geographical region. And if you’re new to advocacy, we can show you how to deal with the media and speak up to legislators.
The 50-State Network has made incredible progress in recent months. Here are a few of them.
HB 279 in Utah passes! Our first advocacy victory of the year: HB 279 in Utah passed! CreakyJoints Patient Advocate Tabatha shared her story before Utah government and humanized an important patient safety concern. Because of her testimony, patients and their physicians must be notified when their biologic or interchangeable biosimilar has been substituted. This victory increases transparency and patient safety.
SB 71 in Colorado passes! In April 2015, thanks in part to CreakyJoints Patient Advocate Mariah’s testimony, SB 71 in Colorado passed! The bill requires patients and their physicians to be notified when their biologic or interchangeable biosimilar has been substituted.
SB 5935 in Washington passes! Our Patient Advocate Lisa shared her story before Washington state government putting patient safety and transparency at the forefront of decision making. Because of her testimony, physicians must be notified when a substitution occurs involving a biologic or interchangeable biosimilar. The bill also has a provision which requires pharmacies to display signage that informs patients that a cheaper interchangeable biosimilar may be available with the consent of their Doctor.
HB 195 in North Carolina passes! Victory number FIVE! Our Patient Advocate Regan submitted her testimony to North Carolina state government putting patient safety and transparency at the forefront of decision making. Because of her testimony, physicians must be notified when a substitution occurs involving a biologic or interchangeable biosimilar. The bill also has a provision which requires the prescribing practitioner the ability to prohibit substitution. Regan’s voice made a difference: As of May 21st, North Carolina Governor McCrory signed House Bill 195 into law!
HB 319 in Louisiana passes! Patient advocates Kat Macfarlane and Candice Dusset were integral in the passing of Louisiana House Bill 319, which was signed into law on July 1st! This bill requires pharmacists to notify prescribers within 5 days if a biologic drug is substituted. Kat testified in front of the state House of Representatives Health and Welfare committee and Candice in front of the state Senate Health and Welfare committee. Featured next to Candice is Rep. Simon, the bill sponsor. Their voices made a difference!
HB 731 in Texas passes! Patient Advocate Cindi Brannum played a key role in the passing of Texas House Bill 751, which was signed into law by Governor Greg Abbott on June 19! In April, Cindi testified before the Texas State Senate Public Health Committee, supporting SB 542 – the companion bill to HB 751. HB 751 requires pharmacists to notify prescribers within three business days if a biologic drug is substituted. The bill also has a provision that requires the prescribing practitioner the ability to prohibit substitution.